BT-001 rectacl cancer
Category: Invir.IO
Colorectal Cancer Hepatic Metastasis Modeling by Advanced 3D Bioprinting Allows Demonstration of Oncolytic Viral Chemotherapeutic Delivery
P. Erbs, et al. Cancers 2025 Abstract available on the MDPI website – Download the article
Transgene and BioInvent to Present Updated Data on Armed Oncolytic virus BT-001 at ESMO 2025
ESMO 2025
TG7010: a Novel Chimeric Oncolytic Poxvirus Encoding IL-12 with Improved Properties for Systemic Delivery
J. Foloppe, et al. IOVC 2024 Abstract available on the IOVC website – Download the abstract and the poster
Oncolytic viruses alter the biogenesis of tumor extracellular vesicles and influence their immunogenicity
U. Hirigoyen, et al. Oncology 2024 Article available on the Molecular Therapy Oncology website – Download the Article
TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvionment
L.Fend, et al. ESMO 2024 Abstract available on the CICON website – Download the abstract and the poster
Transgene to Present Data on its Two Therapeutic Cancer Vaccins at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Transgene to present data on its two therapeutic cancer vaccines at the 2023 ASCO annual meeting
Transgene and BioInvent report positive Phase Ia data on oncolytic virus BT-001 in solid tumors
Transgene and BioInvent report positive Phase Ia data on oncolytic virus BT-001
Transgene – First Patient Dosed in Phase I Trial Evaluating TG6050, a Novel IL-12-Armed Oncolytic Virus Administrated Intravenously, in Non-Small Cell Lung Cancer
First patient dosed in Phase I trial evaluating TG6050 15
Advanced patient-derived lung tumoroids to identify limiting factors for oncolytic virotherapy
H. Le et al.AACR 2023Download the poster herePoster Presentation